Ina Jochmans

Prof. Dr. Ina Jochmans

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2018 in Nature
Verified
Journal Article
Closed access
PDF file
FEfor the Consortium for Organ Preservation in Europe
for the Consortium for Organ Preservation in Europe
DNDavid Nasralla
David Nasralla
CCConstantin Coussios
Constantin Coussios
HMHynek Mergental
Hynek Mergental
MAM. Zeeshan Akhtar
M. Zeeshan Akhtar
PFPeter J. Friend
Peter J. Friend

1 August 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CWChristopher J. E. Watson
Christopher J. E. Watson
VKVasilis Kosmoliaptsis
Vasilis Kosmoliaptsis
CPCaitlin Pley
Caitlin Pley
LRLucy Randle
Lucy Randle
CFCorinna Fear
Corinna Fear
ABAndrew J. Butler
Andrew J. Butler
Normothermic ex situ liver perfusion might allow viability assessment of livers before transplantation. Perfusion characteristics were studied in 47 liver perfusions, of which 22 resulted in transplants. Hepatocellular damage was reflected in the perfusate transaminase concentrations, which correlated with post-transplant peak transaminase levels. Lactate clearance occurred within 3 hours in 46 of 47 perfusions, and glucose rose initially during perfusion in 44. Three livers required higher levels of bicarbonate support to maintain physiological pH, including one developing primary non-function. Bile production did not correlate with viability or cholangiopathy, but bile pH, measured in 16 of the 22 transplanted livers, identified 3 livers that developed cholangiopathy (peak pH7.5). In the 11 research livers where it could be studied, bile pH >7.5 discriminated between the 6 livers exhibiting >50% circumferential stromal necrosis of septal bile ducts and 4 without necrosis; one liver with 25-50% necrosis had a maximum pH 7.46. Liver viability during normothermic perfusion can be assessed using a combination of transaminase release, glucose metabolism, lactate clearance and maintenance of acid-base balance. Evaluation of bile pH may offer a valuable insight into bile duct integrity and risk of post-transplant ischaemic cholangiopathy.

1 November 2010 in Annals of Surgery
Verified
Journal Article
Closed access
IJIna Jochmans
Ina Jochmans
CMCyril Moers
Cyril Moers
JSJacqueline M. Smits
Jacqueline M. Smits
HLHenri Leuvenink
Henri Leuvenink
JTJürgen Treckmann
Jürgen Treckmann
JPJacques Pirenne
Jacques Pirenne
Hypothermic machine perfusion may improve outcome after transplantation of kidneys donated after cardiac death (DCD), but no sufficiently powered prospective studies have been reported. Because organ shortage has led to an increased use of DCD kidneys, we aimed to compare hypothermic machine perfusion with the current standard of static cold storage preservation. Eighty-two kidney pairs from consecutive, controlled DCD donors 16 years or older were included in this randomized controlled trial in Eurotransplant. One kidney was randomly assigned to machine perfusion and the contralateral kidney to static cold storage according to computer-generated lists created by the permuted block method. Kidneys were allocated according to standard rules, with concealment of the preservation method. Primary endpoint was delayed graft function (DGF), defined as dialysis requirement in the first week after transplantation. All 164 recipients were followed until 1 year after transplantation. Machine perfusion reduced the incidence of DGF from 69.5% to 53.7% (adjusted odds ratio: 0.43; 95% confidence interval 0.20–0.89; P = 0.025). DGF was 4 days shorter in recipients of machine-perfused kidneys (P = 0.082). Machine-perfused kidneys had a higher creatinine clearance up to 1 month after transplantation (P = 0.027). One-year graft and patient survival was similar in both groups (93.9% vs 95.1%). Hypothermic machine perfusion was associated with a reduced risk of DGF and better early graft function up to 1 month after transplantation. Routine preservation of DCD kidneys by hypothermic machine perfusion is therefore advisable.

1 March 2018 in Annals of Surgery
Verified
Journal Article
Closed access
XMXavier Muller
Xavier Muller
FMFrancesca Marcon
Francesca Marcon
GSGonzalo Sapisochin
Gonzalo Sapisochin
MMMax Marquez
Max Marquez
FDFederica Dondero
Federica Dondero
PCPierre-Alain Clavien
Pierre-Alain Clavien
This multicentric study of 17 high-volume centers presents 12 benchmark values for liver transplantation. Those values, mostly targeting markers of morbidity, were gathered from 2024 “low risk” cases, and may serve as reference to assess outcome of single or any groups of patients. To propose benchmark outcome values in liver transplantation, serving as reference for assessing individual patients or any other patient groups. Best achievable results in liver transplantation, that is, benchmarks, are unknown. Consequently, outcome comparisons within or across centers over time remain speculative. Out of 7492 liver transplantation performed in 17 international centers from 3 continents, we identified 2024 low risk adult cases with a laboratory model for end-stage liver disease score ≤20 points, a balance of risk score ≤9, and receiving a primary graft by donation after brain death. We chose clinically relevant endpoints covering intra- and postoperative course, with a focus on complications graded by severity including the complication comprehensive index (CCI®). Respective benchmarks were derived from the median value in each center, and the 75 percentile was considered the benchmark cutoff. Benchmark cases represented 8% to 49% of cases per center. One-year patient-survival was 91.6% with 3.5% retransplantations. Eighty-two percent of patients developed at least 1 complication during 1-year follow-up. Biliary complications occurred in one-fifth of the patients up to 6 months after surgery. Benchmark cutoffs were ≤4 days for ICU stay, ≤18 days for hospital stay, ≤59% for patients with severe complications (≥ Grade III) and ≤42.1 for 1-year CCI®. Comparisons with the next higher risk group (model for end stage liver disease 21–30) disclosed an increase in morbidity but within benchmark cutoffs for most, but not all indicators, while in patients receiving a second graft from 1 center (n = 50) outcome values were all outside of benchmark values. Despite excellent 1-year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.

17 February 2011 in Transplant International
Verified
Journal Article
Open access
PDF file
JTJürgen Treckmann
Jürgen Treckmann
CMCyril Moers
Cyril Moers
JSJacqueline M. Smits
Jacqueline M. Smits
AGAnja Gallinat
Anja Gallinat
MMMark-Hugo J. Maathuis
Mark-Hugo J. Maathuis
APAndreas Paul
Andreas Paul
The purpose of this study was to analyze the possible effects of machine perfusion (MP) versus cold storage (CS) on delayed graft function (DGF) and early graft survival in expanded criteria donor kidneys (ECD). As part of the previously reported international randomized controlled trial 91 consecutive heart‐beating deceased ECDs – defined according to the United Network of Organ Sharing definition – were included in the study. From each donor one kidney was randomized to MP and the contralateral kidney to CS. All recipients were followed for 1 year. The primary endpoint was DGF. Secondary endpoints included primary nonfunction and graft survival. DGF occurred in 27 patients in the CS group (29.7%) and in 20 patients in the MP group (22%). Using the logistic regression model MP significantly reduced the risk of DGF compared with CS (OR 0.460, P = 0.047). The incidence of nonfunction in the CS group (12%) was four times higher than in the MP group (3%) (P = 0.04). One‐year graft survival was significantly higher in machine perfused kidneys compared with cold stored kidneys (92.3% vs. 80.2%, P = 0.02). In the present study, MP preservation clearly reduced the risk of DGF and improved 1‐year graft survival and function in ECD kidneys. (Current Controlled Trials number: ISRCTN83876362).

1 November 2020 in The Lancet
Verified
Journal Article
Closed access
IJIna Jochmans
Ina Jochmans
ABAukje Brat
Aukje Brat
LDLucy Davies
Lucy Davies
HHH Sijbrand Hofker
H Sijbrand Hofker
FLFenna E M van de Leemkolk
Fenna E M van de Leemkolk
DYDirk Ysebaert
Dirk Ysebaert